Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Orthobiologics in knee osteoarthritis, dream or reality?

Budhiparama NC., Putramega D., Lumban-Gaol I.

Clinical Trial on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Scar, published in Arch Orthop Trauma Surg (2024) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Arch Orthop Trauma Surg (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38630251
PMCID
PMC11564396
DOI
10.1007/s00402-024-05310-9
Citations
9

Abstract (original English)

Cartilage restoration or repair, also known as orthobiologic therapy, is indicated after the failure of conservative or supportive treatment. However, there is paucity in evidence supporting the efficacy of orthobiologic therapy. The blood-derived products, such as platelet-rich plasma (PRP), is one of the commonly used orthobiologic therapy for knee osteoarthritis. Several studies have shown that PRP is superior to other treatments, but the anatomic changes are scarce. Treatment with mesenchymal stem cells (MSCs) offers the greatest potential for curing degenerative disease due to their self-renewal ability, ability to migrate towards injured tissues (homing/trafficking), and ability to promote repair and regeneration of osteochondral defects. However, ethical concerns and high costs remain major challenges associated with MSC therapy. Gene therapy, another promising orthobiologic therapy, is currently in phase II clinical trial and has shown promising results. The key factors for successful orthobiologic therapy include patient selection, appropriate dosing, treatment of underlying mechanical problems, age, severity, and cost-effectiveness.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansOsteoarthritis, KneeBiological TherapyMesenchymal Stem Cell TransplantationPlatelet-Rich PlasmaGenetic Therapy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research